

Kristina Lindemann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3430601/publications.pdf>

Version: 2024-02-01

49
papers

946
citations

516710

16
h-index

477307

29
g-index

51
all docs

51
docs citations

51
times ranked

1710
citing authors

#	ARTICLE	IF	CITATIONS
1	C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. <i>International Journal of Cancer</i> , 2005, 113, 678-682.	5.1	227
2	Long-Term Outcomes After Pelvic Radiation for Early-Stage Endometrial Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3951-3956.	1.6	86
3	Serum lipids and endometrial cancer risk: Results from the HUNT study. <i>International Journal of Cancer</i> , 2009, 124, 2938-2941.	5.1	51
4	Patterns of Lymph Node Metastases in Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter Study. <i>Annals of Surgical Oncology</i> , 2017, 24, 2720-2726.	1.5	44
5	PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer. <i>The Cochrane Library</i> , 2019, 2019, CD012160.	2.8	43
6	Endometrial cancer incidence trends in Norway during 1953–2007 and predictions for 2008–2027. <i>International Journal of Cancer</i> , 2010, 127, 2661-2668.	5.1	42
7	Risk Stratification of Endometrial Cancer Patients: FIGO Stage, Biomarkers and Molecular Classification. <i>Cancers</i> , 2021, 13, 5848.	3.7	40
8	Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist). <i>British Journal of Cancer</i> , 2017, 116, 455-463.	6.4	33
9	Enhanced Recovery After Surgery for Advanced Ovarian Cancer: A Systematic Review of Interventions Trialed. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1274-1282.	2.5	32
10	Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance. <i>Gynecologic Oncology</i> , 2018, 150, 239-246.	1.4	32
11	Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO). <i>BMC Cancer</i> , 2014, 14, 68.	2.6	30
12	The impact of body mass index and height on the risk for glioblastoma and other glioma subgroups: a large prospective cohort study. <i>Neuro-Oncology</i> , 2016, 19, now272.	1.2	29
13	Overweight, obesity and height as risk factors for meningioma, glioma, pituitary adenoma and nerve sheath tumor: a large population-based prospective cohort study. <i>Acta Oncologica</i> , 2017, 56, 1302-1309.	1.8	26
14	L1CAM as a prognostic marker in stage I endometrial cancer: a validation study. <i>BMC Cancer</i> , 2016, 16, 596.	2.6	25
15	Detection of Micrometastatic Disease in Bone Marrow: Is It Ready for Prime Time?. <i>Oncologist</i> , 2005, 10, 480-492.	3.7	19
16	Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome. <i>Gynecologic Oncology</i> , 2016, 142, 458-464.	1.4	17
17	Body mass index, diabetes and survival after diagnosis of endometrial cancer: A report from the HUNT-Survey. <i>Gynecologic Oncology</i> , 2015, 139, 476-480.	1.4	16
18	Distress, problems and unmet rehabilitation needs after treatment for gynecological cancer. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2022, 101, 313-322.	2.8	15

#	ARTICLE	IF	CITATIONS
19	Enhanced Recovery After Surgery for Suspected Ovarian Malignancy. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1046-1050.	2.5	11
20	Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer – a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34). <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1997-2001.	2.5	11
21	Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 407.e1-407.e16.	1.3	11
22	Self-reported cognitive impairment in cervical cancer survivors: A cross-sectional study. <i>Psycho-Oncology</i> , 2022, 31, 298-305.	2.3	10
23	Clinical pathways of recovery after surgery for advanced ovarian/tubal/peritoneal cancer: an NSGO-MaNGO international survey in collaboration with AGO – a focus on surgical aspects. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 181-187.	2.5	9
24	Clinical Outcome of Patients With High-Risk Endometrial Carcinoma After Treatment With Chemotherapy Only. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1789-1795.	2.5	7
25	Salvage Radiation for Pelvic Relapse after Surgically Treated Endometrial Cancer. <i>Cancers</i> , 2021, 13, 1367.	3.7	7
26	The PROMova study comparing active and passive use of patient-reported outcome measures in ovarian cancer follow-up: effect on patient-perceived involvement, satisfaction with care, and usefulness. <i>Acta Oncologica</i> , 2021, 60, 434-443.	1.8	7
27	Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION interim analysis. <i>Journal of Clinical Oncology</i> , 2020, 38, 6057-6057.	1.6	7
28	Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (<sc>RESPONSE</sc> trial). <i>Cancer</i> , 2022, 128, 3080-3089.	4.1	7
29	Lifestyle and Empowerment Techniques in Survivorship of Gynaecologic Oncology (LETSGO study): a study protocol for a multicentre longitudinal interventional study using mobile health technology and biobanking. <i>BMJ Open</i> , 2021, 11, e050930.	1.9	6
30	Early referral to a palliative team improves end-of-life care among gynecological cancer patients: a retrospective, population-based study. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 181-188.	2.5	6
31	Comparison of the Idylla, MSI assay with the Promega, MSI Analysis System and immunohistochemistry on formalin-fixed paraffin-embedded tissue of endometrial carcinoma: results from an international, multicenter study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 1031-1039.	2.8	6
32	Smoking, obesity and the risk of pituitary adenoma: a large prospective cohort study (The HUNT Study). <i>European Journal of Epidemiology</i> , 2016, 31, 95-98.	5.7	5
33	Survival after radiation therapy for early-stage endometrial carcinoma: The Oslo study revisited after up to 43 years of follow-up. <i>Journal of Clinical Oncology</i> , 2012, 30, 5008-5008.	1.6	5
34	Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103). <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 97-105.	2.3	3
35	Preferences for follow up in long-term survivors after cervical cancer. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2020, 99, 1253-1259.	2.8	3
36	Use of PROM during follow-up of patients with ovarian cancer: the PROMova study protocol. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1444-1449.	2.5	3

#	ARTICLE	IF	CITATIONS
37	AGO-OVAR 2.29 (ENGOT-ov34): Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer (ROC).. Journal of Clinical Oncology, 2019, 37, TPS5601-TPS5601.	1.6	3
38	Age-related differences in self-report and objective measures of cognitive function in older patients prior to chemotherapy. Nursing Open, 2022, 9, 1040-1051.	2.4	3
39	A Call for New Communication Channels for Gynecological Oncology Trainees. International Journal of Gynecological Cancer, 2017, 27, 620-626.	2.5	2
40	Assessment of palliative care training in gynaecological oncology: a survey among European Network of Young Gynae-Oncologists (ENYGO) members. BMJ Supportive and Palliative Care, 2020, , bmjspcare-2020-002233.	1.6	2
41	PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer. The Cochrane Library, 2016, , .	2.8	1
42	Self-management and adherence to recommended follow-up after gynaecological cancer: results from the international InCHARGE study. International Journal of Gynecological Cancer, 2021, 31, 1106-1115.	2.5	1
43	Real-life data of niraparib maintenance treatment in patients with recurrent platinum-sensitive ovarian cancer.. Journal of Clinical Oncology, 2021, 39, 5560-5560.	1.6	1
44	Association of patient-reported outcomes and ovarian cancer recurrence. International Journal of Gynecological Cancer, 2021, 31, 1248-1259.	2.5	1
45	Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome.. Journal of Clinical Oncology, 2016, 34, 5553-5553.	1.6	1
46	A Special Key for Unlocking the Door to Targeted Therapies of Breast Cancer. Scientific World Journal, The, 2008, 8, 905-908.	2.1	0
47	Prediagnostic diabetes, body mass index, and survival of endometrial cancer: A prospective study.. Journal of Clinical Oncology, 2014, 32, 5601-5601.	1.6	0
48	End of life care in gynaecological cancer patients: A population-based study of cancer deaths from the Swedish Register of Palliative Care.. Journal of Clinical Oncology, 2018, 36, 10028-10028.	1.6	0
49	AGO-OVAR 2.29 (ENGOT-ov34): Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer (ROC).. Journal of Clinical Oncology, 2022, 40, TPS5611-TPS5611.	1.6	0